Working…
ClinicalTrials.gov
ClinicalTrials.gov Menu
Help guide our efforts to modernize ClinicalTrials.gov.
Send us your comments by March 14, 2020.
Trial record 10 of 10 for:    LCQ908

A 12 Week Study in Patients With Type 2 Diabetes Mellitus (T2DM)

The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our disclaimer for details.
 
ClinicalTrials.gov Identifier: NCT00901979
Recruitment Status : Completed
First Posted : May 14, 2009
Last Update Posted : January 9, 2013
Sponsor:
Information provided by (Responsible Party):
Novartis ( Novartis Pharmaceuticals )

Brief Summary:
This study will assess the effect of LCQ when added to metformin.

Condition or disease Intervention/treatment Phase
Type 2 Diabetes Mellitus Drug: LCQ908A Drug: Placebo Drug: Sitagliptin Drug: metformin Phase 2

Layout table for study information
Study Type : Interventional  (Clinical Trial)
Actual Enrollment : 693 participants
Allocation: Randomized
Intervention Model: Parallel Assignment
Masking: Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)
Primary Purpose: Treatment
Study Start Date : April 2009
Actual Primary Completion Date : June 2010
Actual Study Completion Date : June 2010

Resource links provided by the National Library of Medicine


Arm Intervention/treatment
Experimental: LCQ908 Dose 1 Drug: LCQ908A
Drug: metformin
Experimental: LCQ908 Dose 2 Drug: LCQ908A
Drug: metformin
Experimental: LCQ908 Dose 3 Drug: LCQ908A
Drug: metformin
Experimental: LCQ908 Dose 4 Drug: LCQ908A
Drug: metformin
Experimental: LCQ908 Dose 5 Drug: LCQ908A
Drug: metformin
Placebo Comparator: Placebo Drug: Placebo
Drug: metformin
Active Comparator: Sitagliptin Drug: Sitagliptin
Drug: metformin



Primary Outcome Measures :
  1. Effect of LCQ on measures of glucose control [ Time Frame: 12 weeks ]

Secondary Outcome Measures :
  1. Changes in body weight and related measures [ Time Frame: 12 weeks ]
  2. Insulin sensitivity [ Time Frame: 12 weeks ]
  3. Safety and tolerability [ Time Frame: 12 weeks ]


Information from the National Library of Medicine

Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the contacts provided below. For general information, Learn About Clinical Studies.


Layout table for eligibility information
Ages Eligible for Study:   18 Years to 75 Years   (Adult, Older Adult)
Sexes Eligible for Study:   All
Accepts Healthy Volunteers:   No
Criteria

Inclusion Criteria:

  • HbA1c from 7.0-10.0%, Stable Metformin dose

Exclusion Criteria:

  • CHF Class III-IV, Liver disease

Other protocol-defined inclusion/exclusion criteria may apply


Information from the National Library of Medicine

To learn more about this study, you or your doctor may contact the study research staff using the contact information provided by the sponsor.

Please refer to this study by its ClinicalTrials.gov identifier (NCT number): NCT00901979


Locations
Show Show 67 study locations
Sponsors and Collaborators
Novartis Pharmaceuticals

Layout table for additonal information
Responsible Party: Novartis Pharmaceuticals
ClinicalTrials.gov Identifier: NCT00901979    
Other Study ID Numbers: CLCQ908A2203
First Posted: May 14, 2009    Key Record Dates
Last Update Posted: January 9, 2013
Last Verified: January 2013
Keywords provided by Novartis ( Novartis Pharmaceuticals ):
Type 2 Diabetes
Additional relevant MeSH terms:
Layout table for MeSH terms
Diabetes Mellitus
Diabetes Mellitus, Type 2
Glucose Metabolism Disorders
Metabolic Diseases
Endocrine System Diseases
Sitagliptin Phosphate
Hypoglycemic Agents
Physiological Effects of Drugs
Incretins
Hormones
Hormones, Hormone Substitutes, and Hormone Antagonists
Dipeptidyl-Peptidase IV Inhibitors
Protease Inhibitors
Enzyme Inhibitors
Molecular Mechanisms of Pharmacological Action